Effect of total sonicated Aggregatibacter actinomycetemcomitans fragments on gingival stem/progenitor cells

BACKGROUND: Aggregatibacter-actinomycetemcomitans (A.actinomycetemcomitans) are strongly associated with localized-aggressive-periodontitis (LAgP). The study's aim was to test for the first time the effect of total sonicated A.actinomycetemcomitans-bacterial-fragments on gingival mesenchymal stem/progenitor cells' (G-MSCs) proliferation and regenerative gene expression in-vitro. MATERIAL AND METHODS: G-MSCs were isolated, characterized, expanded and stimulated by total sonicated A.actinomycetemcomitans-bacterial-fragments (0 (negative-control), 15, 60, 120 and 240μg/ml; serovar-b; n=6/group). Cellular proliferation and NF-κβ (NFKB1), Alkaline Phosphatase (ALPL), Collagen-I (COL1A1), Collagen-III (COL3A1), Osteonectin (SPARC) and Osteopontin (SPP1) m-RNA expression were assessed via reverse-transcription-polymerase-chain-reaction (RT-PCR) at 24, 48 and 72 hours and CFUs-ability evaluated at twelve days. RESULTS: G-MSCs demonstrated stem/progenitor cells' characteristics. A.actinomycetemcomitans-bacterial-fragments (up to 72 hours) resulted in marked G-MSCs' proliferation over-time (p < 0.001) and elevated NFKB1 (p= 0.017), COL1A1 (p = 0.025), SPARC (p = 0.025), decreased ALPL (p = 0.017), with no significant differences for COL3A1 and SPP1 expression or stimulation times (p > 0.05; Friedman-test). Longer-term stimulation for twelve days reduced G-MSCs' CFUs. CONCLUSIONS: Sonicated A.actinomycetemcomitans-bacterial-fragments' exert beneficial short-term effects on G-MSCs' proliferative and non-mineralized tissue forming aptitude. Results shed new light on the importance of periodontal treatment for LAgP patients, using power driven sonic/ultrasonic devices, which, in addition to reducing the subgingival microbial load, produces cell-stimulatory A.actinomycetemcomitans-bacterial-fragments, with positive attributes on tissue reparative/regenerative responses of tissue resident stem/progenitor cells in their niche

Agranulocitosis en paciente en tratamiento con oxcarbacepina que, tras su retirada, se evidenció recuperación de neutrófilos / Agranulocytosis in a patient in oxcarbazepine treatment, after its withdrawal, neutrophils returned to a normal levels

No disponible

SEOM clinical guidelines for myeloid growth factors

Neutropenia induced by chemotherapy (CT) is an infection risk factor associated to greater morbidity/mortality and dose-limiting toxicity that on many occasions requires a reduction of the dose of cytostatics or a delay in the administration of treatment. This may have a negative effect on the patient's quality of life and even diminish the efficacy of the treatment, especially when the intention is to cure or prolong survival. Management of treatment or prophylaxis of grade 3-4 neutropenia and febrile neutropenia with myeloid growth factors (CSF) varies very much in clinical practice, both in the time of starting treatment and the types of patients it is given to. The need to generalise and facilitate practice based on clinical evidence has led the Spanish Society of Medical Oncology (SEOM) to prepare clinical practice guidelines on the use of myeloid growth factors (AU)

Factores estimuladores de colonias. Consejos para la autoadministración / Self-administration of colony stimulating factors (CSF'S): basic advice

Como profesionales de enfermería conocemos la importancia de impartir una buena educación sanitaria para conseguir la máxima autonomía en nuestros pacientes. Como enfermeras de una Unidad de Hospital de día médico, en el que tratamos pacientes oncológicos y oncohematológicos que necesitan tratamiento con factores de estimulación de colonias, hemos creído oportuno la elaboración de un díptico informativo sobre la autoadministración de los mismos. Es cierto que los pacientes, gracias a los diferentes medios de comunicación, reciben mucha información pero, desgraciadamente, puede llegar de manera distorsionada, poco comprensible y -en ocasiones- de forma no del todo lícita. Nuestro objetivo es reforzar la autoadministración de este medicamento o, en su defecto, la aplicación por el cuidador principal o familiar. Tras varias pruebas, hemos optado por un díptico más visual que escrito porque creemos que una imagen vale más que mil palabras(AU)

As nurses we all know the importance of good health education to achieve the highest level of autonomy in our patients. In the Medical Day Unit of Palamós Hospital we treat cancer patients who need CSF's (Colony Stimulating Factors) medication. We thought it would be appropriate, therefore, to draw up an information leaflet on self-administration of CSF's. These kind of patients receive a lot of information through the different media but, unfortunately, it can get distorted, unclear, and often, not at all lawful. Our goal is that the patient or, in his absence, the main career can improve the self-administration of the drug. After several tests we have opted for a visual leaflet instead of a written one because we believe that «a picture is worth a thousand words»(AU)

Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients

Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens (AU)

El estudio FAST falla en demostrar la eficacia del factor VIIa recombinante en la hemorragia intracerebral / The FAST study fails to demonstrate the effectiveness of recombinant factor VIIa in intracerebral haemorrhage

No disponible

Estudio multicéntrico del tratamiento empírico de la neutropenia febril en el enfermo oncohematológico / Multicentric study of empiric treatment of febrile neutiropenia in cancer patients

En el presente trabajo se analiza un estudio multicéntrico de tipo prospectivo, cuyo principal objetivo es conocer el perfil de utilización de antibióticos y antifúngicos empleados en el tratamiento de la neutropenia febril en el paciente oncohematológico y establecer el grado de adhesión a los protocolos instaurados en siete hospitales de la zona Andalucía Oriental. Se incluyeron en el estudio los pacientes que recibieron tratamiento durante el período mayo-junio de 1998 (65 episodios), utilizando para su evaluación unas hojas de recogida de datos consensuadas por los hospitales participantes. En ellas también se recoge la utilización de factores estimulantes de colonias en estos pacientes. Los resultados muestran que la monoterapia genera un interés creciente como alternativa a la terapia combinada, especialmente en pacientes de bajo riesgo. La mayoría de los hospitales participantes poseen protocolos instaurados que recogen el tratamiento antiinfeccioso empírico de la neutropenia febril, variando el grado de adhesión entre un 50 y un 75 por ciento. Destaca la utilización de factores estimulantes de colonias en un alto porcentaje de pacientes (72,3 por ciento) como terapia adyuvante (AU)